Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

NCT02557321 is registered in ClinicalTrials.gov with Provectus Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT02557321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02557321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2015
Completion date
April 30, 2025
Enrollment
50 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma